Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.

Kim S, Buecher B, André T, Jary M, Bidard FC, Ghiringhelli F, François É, Taieb J, Smith D, de la Fouchardière C, Desramé J, Samalin E, Parzy A, Baba-Hamed N, Bouché O, Tougeron D, Dahan L, El Hajbi F, Jacquin M, Rebucci-Peixoto M, Spehner L, Vendrely V, Vernerey D, Borg C

Open source

DOI: 10.1186/s12885-020-06841-1
Published: 2020 Apr 25
Container: BMC cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s12885-020-06841-1,
  title = {Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.},
  author = {Kim S and Buecher B and André T and Jary M and Bidard FC and Ghiringhelli F and François É and Taieb J and Smith D and de la Fouchardière C and Desramé J and Samalin E and Parzy A and Baba-Hamed N and Bouché O and Tougeron D and Dahan L and El Hajbi F and Jacquin M and Rebucci-Peixoto M and Spehner L and Vendrely V and Vernerey D and Borg C},
  year = {2020},
  journal = {BMC cancer},
  doi = {10.1186/s12885-020-06841-1},
  url = {https://doi.org/10.1186/s12885-020-06841-1}
}

RIS

TY  - JOUR
TI  - Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
AU  - Kim S
AU  - Buecher B
AU  - André T
AU  - Jary M
AU  - Bidard FC
AU  - Ghiringhelli F
AU  - François É
AU  - Taieb J
AU  - Smith D
AU  - de la Fouchardière C
AU  - Desramé J
AU  - Samalin E
AU  - Parzy A
AU  - Baba-Hamed N
AU  - Bouché O
AU  - Tougeron D
AU  - Dahan L
AU  - El Hajbi F
AU  - Jacquin M
AU  - Rebucci-Peixoto M
AU  - Spehner L
AU  - Vendrely V
AU  - Vernerey D
AU  - Borg C
PY  - 2020
JO  - BMC cancer
DO  - 10.1186/s12885-020-06841-1
UR  - https://doi.org/10.1186/s12885-020-06841-1
ER  -

APA

S, K., B, B., T, A., M, J., FC, B., F, G., É, F., J, T., D, S., C, D. L. F., J, D., E, S., A, P., N, B., O, B., D, T., L, D., F, E. H., M, J., M, R., L, S., V, V., D, V., & C, B. (2020). Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.. BMC cancer. https://doi.org/10.1186/s12885-020-06841-1

Source records

pubmed · retrieved 2026-09-26T23:57:18.772Z